S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Wall Street Legend Who Called AMZN Crash Issues New Sell Alert (Ad)
Biden and GOP rush to finalize debt ceiling deal, shore up support to prevent default
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Wall Street Legend Who Called AMZN Crash Issues New Sell Alert (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Wall Street Legend Who Called AMZN Crash Issues New Sell Alert (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Wall Street Legend Who Called AMZN Crash Issues New Sell Alert (Ad)
Biden and GOP rush to finalize debt ceiling deal, shore up support to prevent default
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Wall Street Legend Who Called AMZN Crash Issues New Sell Alert (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Wall Street Legend Who Called AMZN Crash Issues New Sell Alert (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Wall Street Legend Who Called AMZN Crash Issues New Sell Alert (Ad)
Biden and GOP rush to finalize debt ceiling deal, shore up support to prevent default
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Wall Street Legend Who Called AMZN Crash Issues New Sell Alert (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Wall Street Legend Who Called AMZN Crash Issues New Sell Alert (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Wall Street Legend Who Called AMZN Crash Issues New Sell Alert (Ad)
Biden and GOP rush to finalize debt ceiling deal, shore up support to prevent default
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Wall Street Legend Who Called AMZN Crash Issues New Sell Alert (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Wall Street Legend Who Called AMZN Crash Issues New Sell Alert (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade

DICE Therapeutics (DICE) Stock Forecast, Price & News

$32.81
-0.34 (-1.03%)
(As of 05/26/2023 ET)
Compare
Today's Range
$32.14
$33.69
50-Day Range
$25.86
$38.24
52-Week Range
$12.64
$45.99
Volume
212,713 shs
Average Volume
452,437 shs
Market Capitalization
$1.57 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$62.60

DICE Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.91 Rating Score
Upside/​Downside
90.8% Upside
$62.60 Price Target
Short Interest
Bearish
20.83% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.66mentions of DICE Therapeutics in the last 14 days
Based on 16 Articles This Week
Insider Trading
Acquiring Shares
$10.24 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.57) to ($3.57) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

323rd out of 1,012 stocks

Pharmaceutical Preparations Industry

137th out of 495 stocks


DICE stock logo

About DICE Therapeutics (NASDAQ:DICE) Stock

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Receive DICE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DICE Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DICE Stock News Headlines

3 Free Stock Picks per Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
DICE Therapeutics (NASDAQ:DICE) Shares Gap Up to $32.66
3 Free Stock Picks per Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
H.C. Wainwright Remains a Buy on Dice Therapeutics (DICE)
Recap: DICE Therapeutics Q1 Earnings
DICE Therapeutics GAAP EPS of -$0.54
See More Headlines
Receive DICE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DICE Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DICE Company Calendar

Last Earnings
3/15/2023
Today
5/28/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DICE
Fax
N/A
Employees
46
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$62.60
High Stock Price Forecast
$77.00
Low Stock Price Forecast
$38.00
Forecasted Upside/Downside
+90.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.91
Research Coverage
11 Analysts

Profitability

Net Income
$-83,890,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.13 million
Book Value
$11.46 per share

Miscellaneous

Free Float
45,392,000
Market Cap
$1.57 billion
Optionable
Not Optionable
Beta
0.69

Key Executives

  • Dr. J. Kevin Judice Ph.D. (Age 58)
    Founder, CEO & Director
    Comp: $765.04k
  • Mr. Scott Robertson
    Chief Bus. & Financial Officer
  • Dr. Timothy Lu M.D. (Age 48)
    Ph.D., Chief Medical Officer
    Comp: $660.44k
  • Dr. John R. Jacobsen Ph.D. (Age 54)
    Chief Scientific Officer
  • Ms. Mary Riley J.D.
    Gen. Counsel
  • Mr. Venkat Thalladi Ph.D.
    Sr. VP of CMC
  • Mr. Paul Fatheree
    Sr. VP of Medicinal Chemistry













DICE Stock - Frequently Asked Questions

Should I buy or sell DICE Therapeutics stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DICE Therapeutics in the last twelve months. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DICE shares.
View DICE analyst ratings
or view top-rated stocks.

What is DICE Therapeutics' stock price forecast for 2023?

11 Wall Street research analysts have issued 12-month target prices for DICE Therapeutics' shares. Their DICE share price forecasts range from $38.00 to $77.00. On average, they predict the company's share price to reach $62.60 in the next twelve months. This suggests a possible upside of 90.8% from the stock's current price.
View analysts price targets for DICE
or view top-rated stocks among Wall Street analysts.

How have DICE shares performed in 2023?

DICE Therapeutics' stock was trading at $31.20 on January 1st, 2023. Since then, DICE shares have increased by 5.2% and is now trading at $32.81.
View the best growth stocks for 2023 here
.

Are investors shorting DICE Therapeutics?

DICE Therapeutics saw a decline in short interest in May. As of May 15th, there was short interest totaling 8,010,000 shares, a decline of 9.0% from the April 30th total of 8,800,000 shares. Based on an average trading volume of 526,900 shares, the short-interest ratio is currently 15.2 days. Currently, 20.8% of the company's stock are short sold.
View DICE Therapeutics' Short Interest
.

When is DICE Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our DICE earnings forecast
.

How were DICE Therapeutics' earnings last quarter?

DICE Therapeutics, Inc. (NASDAQ:DICE) announced its quarterly earnings results on Wednesday, March, 15th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.49) by $0.02.

When did DICE Therapeutics IPO?

(DICE) raised $160 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 10,000,000 shares at a price of $15.00-$17.00 per share.

What is DICE Therapeutics' stock symbol?

DICE Therapeutics trades on the NASDAQ under the ticker symbol "DICE."

Who are DICE Therapeutics' major shareholders?

DICE Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (11.90%), Avoro Capital Advisors LLC (8.28%), Price T Rowe Associates Inc. MD (6.82%), BlackRock Inc. (6.31%), Armistice Capital LLC (2.88%) and Baker BROS. Advisors LP (2.17%). Insiders that own company stock include James Paul Scopa, John R Jacobsen, Kevin Judice, Lu Timothy, Ra Capital Management, LP, Richard H Scheller and Scott M Robertson.
View institutional ownership trends
.

How do I buy shares of DICE Therapeutics?

Shares of DICE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DICE Therapeutics' stock price today?

One share of DICE stock can currently be purchased for approximately $32.81.

How much money does DICE Therapeutics make?

DICE Therapeutics (NASDAQ:DICE) has a market capitalization of $1.57 billion and generates $1.13 million in revenue each year. The company earns $-83,890,000.00 in net income (profit) each year or ($2.18) on an earnings per share basis.

How can I contact DICE Therapeutics?

DICE Therapeutics' mailing address is 279 E. GRAND AVENUE SUITE 300 LOBBY B, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.dicemolecules.com. The company can be reached via phone at 650-566-1420 or via email at investors@dicetx.com.

This page (NASDAQ:DICE) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -